MacEwan, A., McKay, G. A. and Fisher, M. (2012) Drugs for diabetes: part 8 SGLT2 inhibitors. British Journal of Cardiology, 19, pp. 26-29. (doi: 10.5837/bjc.2012.005)
Full text not currently available from Enlighten.
Abstract
GLT2 inhibitors are a new class of oral drugs for the treatment of type 2 diabetes mellitus currently in phase III studies. They inhibit glucose re-absorption in the proximal renal tubules providing an insulin independent mechanism to lower blood glucose. Their use in clinical practice is associated with improved glycaemic control, weight loss and a low risk of hypoglycaemia. Phase III cardiovascular safety studies are ongoing.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | McKay, Dr Gerard |
| Authors: | MacEwan, A., McKay, G. A., and Fisher, M. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
| Journal Name: | British Journal of Cardiology |
| Journal Abbr.: | Br J Cardiol |
| Publisher: | MediNews Limited |
| ISSN: | 0969-6113 |
| ISSN (Online): | 1753-4313 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details